You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER-2 positive; brain metastases

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Combination use of SRT with T-DXd
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 14, 2023

Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)

Recruiting
  • Breast Cancer With Brain Metastases
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023

Brain Metastases, HER2-positive Breast Cancer Trial (Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine)

Not yet recruiting
  • Brain Metastases
  • HER2-positive Breast Cancer
  • Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
  • (no location specified)
Jan 10, 2023

Breast Cancer, Brain Metastases, HER2-positive Breast Cancer Trial in Shanghai (Pyrotinib Plus Capecitabine combined with brain

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Pyrotinib Plus Capecitabine combined with brain radiotherapy
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jan 14, 2023

Metastatic Breast Cancer Trial in Zhengzhou (SHR-A1811, Pyrotinib, Bevacizumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Mar 13, 2023

A Nationwide Multicenter, Ambispective Real-world Study of

Recruiting
  • Breast Cancer
    • Zhengzhou, Henan, China
      Henan cancer hospital
    Sep 15, 2022

    T-Dxd in Treatment of HER2-positive BCBM After Prior Pyrotinib

    Recruiting
    • Breast Cancer
    • Beijing, Beijing, China
    • +1 more
    Nov 13, 2023

    Breast Cancer Brain Metastases Trial in Guangzhou (SPH4336 Tablets)

    Not yet recruiting
    • Breast Cancer Brain Metastases
    • SPH4336 Tablets
    • Guangzhou, Guangdong, China
      Affiliated Cancer Hospital, Sun Yat-sen University
    May 24, 2023

    Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)

    Not yet recruiting
    • Metastatic Solid Tumor
    • Brain Metastases
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 30, 2022

    Brain Metastases, HR+ Metastatic Breast Cancer Trial in Tampa (Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy)

    Recruiting
    • Brain Metastases
    • HR+ Metastatic Breast Cancer
    • Stereotactic Radiosurgery (SRS)
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 1, 2022

    Breast Cancer, Brain Metastases, HER2-positive Breast Cancer Trial in Los Angeles (Tucatinib, Pembrolizumab, Trastuzumab)

    Withdrawn
    • Breast Cancer
    • +3 more
    • Los Angeles, California
      Cedars-Sinai Medical Center
    Jun 28, 2022

    Breast Cancer Stage IV Trial in Vienna (Trastuzumab deruxtecan)

    Active, not recruiting
    • Breast Cancer Stage IV
    • Trastuzumab deruxtecan
    • Vienna, Austria
      AKH Universitaetsklinikum Vienna, Department f. Internal medicin
    Jul 26, 2022

    Malignant Tumor, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Duarte

    Recruiting
    • Malignant Neoplasm
    • +4 more
    • Chimeric Antigen Receptor T-Cell Therapy
    • Duarte, California
      City of Hope Medical Center
    Sep 14, 2022

    HER2 Positive Metastatic Breast Cancer Trial in Zhengzhou (Pyrotinib plus Capecitabine)

    Active, not recruiting
    • HER2 Positive Metastatic Breast Cancer
    • Pyrotinib plus Capecitabine
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Dec 9, 2021

    HER2-positive Metastatic Breast Cancer Trial in Nanchang (radiation combined with pyrotinib and capecitabine)

    Recruiting
    • HER2-positive Metastatic Breast Cancer
    • radiation combined with pyrotinib and capecitabine
    • Nanchang, Jiangxi, China
      Jiangxi Cancer Hospital of Nanchang University
    Feb 12, 2022

    Breast Cancer Trial in Boston (Trastuzumab, GDC-0084)

    Recruiting
    • Breast Cancer
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Mar 2, 2022

    Breast Cancer, Brain Metastases Trial in Guangzhou (Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant)

    Recruiting
    • Breast Cancer
    • Brain Metastases
    • Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
    • Guangzhou, Guangdong, China
    • +1 more
    Apr 24, 2022

    Breast Cancer, Brain Metastases Trial (Neratinib)

    Withdrawn
    • Breast Cancer
    • Brain Metastases
    • (no location specified)
    Feb 28, 2022

    Breast Cancer, Brain Metastases Trial in Toronto (ExAblate BBBD)

    Recruiting
    • Breast Cancer
    • Brain Metastases
    • ExAblate BBBD
    • Toronto, Ontario, Canada
      Sunnybrook Health Sciences Centre
    Aug 23, 2021

    Breast Cancer Trial in United States (HKI-272, Surgical Resection, Capecitabine)

    Active, not recruiting
    • Breast Cancer
    • San Francisco, California
    • +17 more
    Jan 30, 2023

    Tumor Metastasis Trial in New York (Intra-arterial Cerebral Infusion of Trastuzumab)

    Terminated
    • Neoplasm Metastasis
    • Intra-arterial Cerebral Infusion of Trastuzumab
    • New York, New York
      Lenox Hill Brain Tumor Center
    Oct 27, 2021

    HER2-positive Breast Cancer, Brain Metastases Trial in Beijing, Guangzhou, Hangzhou (Trastuzumab, Taxanes, Pertuzumab)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Brain Metastases
    • Beijing, Beijing, China
    • +2 more
    May 28, 2021

    Brain Cancer, Brain Metastases, Melanoma Trial in Boston (radiation, drug, other)

    Recruiting
    • Brain Cancer
    • +15 more
    • Stereotactic Radiation
    • +2 more
    • Boston, Massachusetts
    • +1 more
    Oct 19, 2021

    Breast Tumors Trial in Melbourne (Local Therapy)

    Active, not recruiting
    • Breast Neoplasms
    • Local Therapy
    • Melbourne, Victoria, Australia
      Peter MacCallum Cancer Centre
    Feb 7, 2021

    Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))

    Not yet recruiting
    • Breast Cancer
    • Metastatic Breast Cancer
    • Trastuzumab-Deruxtecan (T-DXd)
    • (no location specified)
    Sep 20, 2023